For head and neck cancer including OSCC, treatment with anti-programmed cell death-1 (anti-PD-1) and anti-programmed cell death ligand-1 (anti-PD-L1) antibodies are crucial in the currently approved immunotherapy (27, 28). The gene discussed is CD274; the disease is head and neck cancer.